As it takes Lartruvo off the shelves, Lilly is setting up program to provide drug access to current patients
When Lilly’s approved soft tissue sarcoma drug Lartruvo unexpectedly failed to help patients live longer in a late-stage study in January, US and EU …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
